A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70596 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Pablo Lapuerta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lapuerta Consulting LLC, Skillman, New Jersey, USA. Hauptthemen laut MEDLINE: Insulin Resistance, Adiponectin, Receptors, Adiponectin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Encuragen.
Abstract (Originalsprache)
Low adiponectin levels may contribute to insulin resistance. This first‐in‐human study evaluated adiponectin receptor agonist (PEG)‐BHD1028 in subjects with insulin resistance. Adults with BMI ≥ 27 kg/m 2 , HOMA‐IR ≥ 1.8, and HbA1c < 6.5% received subcutaneous injections of (PEG)‐BHD1028 or placebo in single‐ascending dose (SAD) cohorts (4, 8, 16, 32, and 64 μg/kg) and multiple‐ascending dose (MAD) cohorts for 28 days (8, 16, and 32 μg/kg QD). Each cohort had eight subjects, with two on placebo. Area under the curve (AUC) was obtained for insulin c‐peptide, insulin, and glucose in a mixed meal tolerance test (MMTT) at Day −1 and Day 28. Body weight, triglycerides, and inflammatory markers were measured at regular intervals. Changes were analyzed by the Kruskal–Wallis test (for MMTT) and generalized estimating equations (GEEs). The MAD cohort mean age was 49 years, with a body mass index of 32, baseline HOMA‐IR 3.8, and 42% female. Mild gastrointestinal adverse events occurred on (PEG)‐BHD1028 (50%) and placebo (33%) without discontinuations. Drug exposure was proportional to dose. Insulin c‐peptide AUC changes were +25% on placebo and −63%, + 24%, and + 2% on (PEG)‐BHD1028 8, 16, and 32 μg/kg doses ( p < 0.001). Reductions in insulin ( p = 0.116) were also observed, with the greatest percentage change on 8 μg/kg. There were no consistent differences between groups in body weight, triglycerides, and inflammatory markers. Adiponectin agonist (PEG)‐BHD1028 was well‐tolerated with dose‐related increases in exposure. Observed effects on insulin c‐peptide and insulin during the MMTT support further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lapuerta Consulting LLC, Skillman, New Jersey, USA.
- EncuraGen Inc., Anyang, Republic of Korea.
ORCID-Profile: Pablo Lapuerta, Brian B Kim
Förderung
- Encuragen
Zitieren
APA
Lapuerta, P., & Kim, B. B. (2026). A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance. Clinical and Translational Science. https://doi.org/10.1111/cts.70596
Vancouver
Lapuerta P, Kim BB. A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance. Clinical and Translational Science. 2026. doi:10.1111/cts.70596
BibTeX
@article{Lapuerta2026,
author = {Lapuerta, Pablo and Kim, Brian B},
title = {A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70596}
}
EUVIMED